HomeBOT • ASX
add
Botanix Pharmaceuticals Ltd
Previous close
$0.22
Day range
$0.21 - $0.22
Year range
$0.076 - $0.24
Market cap
323.26M AUD
Avg Volume
3.27M
P/E ratio
-
Dividend yield
-
Primary exchange
ASX
Market news
Financials
Income Statement
Revenue
Net income
(AUD) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | 188.96K | -89.82% |
Operating expense | 2.46M | 52.31% |
Net income | -2.73M | -18.93% |
Net profit margin | -1.45K | -1,068.51% |
Earnings per share | — | — |
EBITDA | -2.76M | -19.90% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
(AUD) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 18.31M | 110.12% |
Total assets | 47.68M | 129.35% |
Total liabilities | 2.29M | -42.92% |
Total equity | 45.39M | — |
Shares outstanding | 1.55B | — |
Price to book | 7.17 | — |
Return on assets | -14.49% | — |
Return on capital | -15.22% | — |
Cash Flow
Net change in cash
(AUD) | Dec 2023info | Y/Y change |
---|---|---|
Net income | -2.73M | -18.93% |
Cash from operations | -1.88M | 34.38% |
Cash from investing | -7.39M | -189.02% |
Cash from financing | 13.38M | 113.26% |
Net change in cash | 4.03M | 463.80% |
Free cash flow | -8.37M | -129.50% |
About
Botanix Pharmaceuticals is listed on the Australian Securities Exchange with the issue code BOT. The Company is headquartered in Perth, Western Australia and Philadelphia, USA. It is a clinical stage synthetic cannabinoid company, focusing on the compound Cannabidiol. The company has two separate development platforms, dermatology and antimicrobial. Botanix also has an exclusive license to use a proprietary drug delivery system Permetrex, for direct skin delivery of active pharmaceuticals which is utilised in all of their programs. Wikipedia
Founded
1984
Website
Employees
11